Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease

References

• Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–S115.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, van Raalte DH, et al. The new biology of diabetic kidney disease-mechanisms and therapeutic implications. Endocr Rev. 2020;41:202–231.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Scheen AJ. Preventing and treating kidney disease in patients with type 2 diabetes. Exp Opin Pharmacother. 2019;20:277–294.
   PubMed Web of Science ®Google Scholar
• Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–586.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229.
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;28. DOI:https://doi.org/10.1056/NEJMoa2110956.
   Google Scholar
• Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(556–77):556–577.
   PubMedGoogle Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–617.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64:1256–1267.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Longo M, Caruso P, et al. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab. 2021;23:1672–1676.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Dagogo-Jack S, McGuire DK, et al. Kidney outcomes using a sustained >/=40% decline in eGFR: a meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021;44:1139–1143.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–854.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–139.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31:1128–1139.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Wissing KM, Scheen AJ. SGLT2 inhibitors: renal outcomes according to baseline albuminuria. Clin Kidney J. 2021. DOI:https://doi.org/10.1093/ckj/sfab096
   Google Scholar
• Jardine M, Zhou Z, Heerspink H, et al. Renal, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria: a Credence secondary analysis. Clin J Am Soc Nephrol. 2021;16:384–395.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2021 May 23. DOI:https://doi.org/10.1053/j.ajkd.2021.05.005.
   Google Scholar
• Packer M, Butler J, Zannad F, et al. Empagliflozin and major renal outcomes in heart failure. N Engl J Med. 2021;385:1531–1533.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opin Drug Safety. 2020;19:243–256.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. An update on the safety of SGLT2 inhibitors. Exp Opin Drug Safety. 2019;18:295–311.
   PubMed Web of Science ®Google Scholar
• Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31:1128–1139.
   PubMed Web of Science ®Google Scholar
• Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119–129.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537–1550.
   PubMed Web of Science ®Google Scholar
• Bakris G, Oshima M, Mahaffey KW, et al. Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol. 2020;15:1705–1714.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Vart P, Jongs N, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32:2352–2361.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol. 2021;16:1278–1280.
   PubMed Web of Science ®Google Scholar
• Perlman A, Heyman SN, Matok I, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27:1108–1113.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin cited 2021 Nov 18
   Google Scholar
• Hahn K, Ejaz AA, Kanbay M, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711–712.
   PubMed Web of Science ®Google Scholar
• Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16:e1002983.
   PubMed Web of Science ®Google Scholar
• Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40:1479–1485.
   PubMed Web of Science ®Google Scholar
• Cahn A, Melzer-Cohen C, Pollack R, et al. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab. 2019;21:340–348.
   PubMed Web of Science ®Google Scholar
• Iskander C, Cherney DZ, Clemens KK, et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ. 2020;192:E351–E60.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes Metab. 2021;47:101275.
   PubMed Web of Science ®Google Scholar
• Sridhar VS, Tuttle KR, Cherney DZI. We can finally stop worrying about SGLT2 inhibitors and acute kidney injury. Am J Kidney Dis. 2020;76:454–456.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94:26–39.
   PubMed Web of Science ®Google Scholar
• Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28:1023–1039.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16:317–336.
   PubMed Web of Science ®Google Scholar
• Saulnier PJ, Looker HC, Mauer M, et al. Intraglomerular dysfunction predicts kidney failure in type 2 diabetes. Diabetes. 2021;70:2344–2352.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Stafylas PC, Kanaki AI, et al. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21:922–929.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996;49:1774–1777.
   PubMed Web of Science ®Google Scholar
• van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97:202–212.
   PubMed Web of Science ®Google Scholar
• Mayer GJ, Wanner C, Weir MR, et al. Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96:489–504.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
   PubMed Web of Science ®Google Scholar
• Ott C, Jung S, Korn M, et al. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20:178.
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Hotchkiss JR, Kurella Tamura M, et al. Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults. JAMA Intern Med. 2014;174:391–397.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.
   PubMed Web of Science ®Google Scholar
• Li J, Neal B, Perkovic V, et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020;98:769–777.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Scheen AJ. The diuretic effect of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021;47:101285.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics. Diabetes Metab. 2016;42:224–233.
   PubMed Web of Science ®Google Scholar
• McMurray J. EMPA-REG - the “diuretic hypothesis”. J Diabetes Complications. 2016;30:3–4.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17:319–334.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128–139.
   PubMed Web of Science ®Google Scholar
• Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68:392–401.
   PubMed Web of Science ®Google Scholar
• Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13:1682–1685.
   PubMed Web of Science ®Google Scholar
• Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005;16:474–481.
   PubMed Web of Science ®Google Scholar
• Trujillo H, Caravaca-Fontan F, Caro J, et al. The forgotten antiproteinuric properties of diuretics. Am J Nephrol. 2021;52:435–449.
   PubMedGoogle Scholar
• Piperidou A, Sarafidis P, Boutou A, et al. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1334–1343.
   PubMed Web of Science ®Google Scholar
• Bae JH, Park EG, Kim S, et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9:13009.
   PubMed Web of Science ®Google Scholar
• Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020;8:553–555.
   PubMed Web of Science ®Google Scholar
• Oshima M, Neuen BL, Li J, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31:2925–2936.
   PubMed Web of Science ®Google Scholar
• Waijer SW, Xie D, Inzucchi SE, et al. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial. J Am Heart Assoc. 2020;9:e016976.
   PubMed Web of Science ®Google Scholar
• Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904–910.
   PubMed Web of Science ®Google Scholar
• Kuriyama S. A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: amelioration of renal congestion. Kidney Blood Press Res. 2019;44:449–456.
   PubMed Web of Science ®Google Scholar
• Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:1178–1195.
   PubMed Web of Science ®Google Scholar
• Verma A, Patel AB, Waikar SS. SGLT2 inhibitor: not a traditional diuretic for heart failure. Cell Metab. 2020;32:13–14.
   PubMed Web of Science ®Google Scholar
• Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138:929–944.
   PubMed Web of Science ®Google Scholar
• Bouquegneau A, Krzesinski JM, Delanaye P, et al. Biomarkers and physiopathology in the cardiorenal syndrome. Clin Chim Acta. 2015;443:100–107.
   PubMed Web of Science ®Google Scholar
• Thakar CV, Christianson A, Himmelfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011;6:2567–2572.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Fitchett D, Kosiborod MN, et al. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2021;23:1085–1093.
   PubMed Web of Science ®Google Scholar
• Hesp AC, Schaub JA, Prasad PV, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020;98:579–589.
   PubMed Web of Science ®Google Scholar
• Packer M. Mechanisms leading to differential hypoxia-Inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77:280–286.
   PubMed Web of Science ®Google Scholar
• Vinovskis C, Li LP, Prasad P, et al. Relative hypoxia and early diabetic kidney disease in type 1 diabetes. Diabetes. 2020;69:2700–2708.
   PubMedGoogle Scholar
• Pruijm M, Milani B, Pivin E, et al. Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int. 2018;93:932–940.
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Inoue T, Kozawa E, et al. Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease. Nephrol Dial Transplant. 2020;35:964–970.
   PubMed Web of Science ®Google Scholar
• Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74:867–872.
   PubMed Web of Science ®Google Scholar
• Layton AT, Vallon V, Edwards A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol. 2016;310:F1269–83.
   PubMed Web of Science ®Google Scholar
• Laursen JC, Sondergaard-Heinrich N, de Melo JML, et al. Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. EClinicalMedicine. 2021;37:100895.
   PubMedGoogle Scholar
• Zhou S, Zhang Y, Wang T, et al. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function. Diabetes Metab. 2021;47:101274.
   PubMed Web of Science ®Google Scholar
• Gilbert RE. SGLT2 inhibitors: beta blockers for the kidney? Lancet Diabetes Endocrinol. 2016;4:814.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43:99–109.
   PubMed Web of Science ®Google Scholar
• Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142:1028–1039.
   PubMed Web of Science ®Google Scholar
• Jensen J, Omar M, Kistorp C, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021;9:106–116.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial. Diabetes Obes Metab. 2021;23:1426–1430.
   PubMed Web of Science ®Google Scholar
• Grodin JL, Tang WHW. Sodium-glucose cotransporter-2 Inhibitors and loop diuretics for heart failure: priming the natriuretic and metabolic reserve of the kidney. Circulation. 2020;142:1055–1058.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63:221–228.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111–S24.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77:94–109.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726.
   PubMed Web of Science ®Google Scholar
• Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer dru gs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021;9:46–52.
   PubMed Web of Science ®Google Scholar
• Rhee JJ, Jardine MJ, Chertow GM, et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020;22(Suppl 1):46–54.
   PubMedGoogle Scholar